Monte Rosa Therapeutics Announced Progress Updates For Its Two Lead Programs, MRT-2359, An MGD Being Developed For MYC-Driven Solid Tumors, And MRT-6160, A VAV1-directed MGD In Development For Systemic And Neurological Autoimmune Diseases
Monte Rosa Therapeutics Announced Progress Updates For Its Two Lead Programs, MRT-2359, An MGD Being Developed For MYC-Driven Solid Tumors, And MRT-6160, A VAV1-directed MGD In Development For Systemic And Neurological Autoimmune Diseases
蒙特羅薩治療公司發佈了兩個主要計劃的進展更新，即MRT-2359和MRT-6160。其中，MRT-2359是針對MYC驅動的實體腫瘤而開發的MDG，而MRT-6160則是針對系統性和神經免疫疾病而開發的VAV1定向MDG。
- Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 2024.
- IND submission achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; initiation of Phase 1 SAD/MAD study expected this summer with Phase 1 clinical data anticipated in Q1 2025.
- MRT-2359用於MYC驅動的實體腫瘤的1/2期臨床研究表現出良好的安全性和藥效學特徵，0.5毫克劑量採用21/7計劃; 目前正在評估0.75毫克劑量水平; 推薦的2期劑量的最終確定以及更新的臨床結果預計將於2024下半年出爐。
- MRT-6160是面向系統性和神經自身免疫疾病開發的以VAV1爲靶向的多肽藥物，並已完成IND提交; SAD/MAD 1期臨床研究預計於今年夏季啓動，1期臨床數據預計於2025 Q1公佈。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。